当前位置: X-MOL 学术Lancet Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Correction to Lancet Oncol 2019; 20: 1432-43.
The Lancet Oncology ( IF 41.6 ) Pub Date : 2020-01-01 , DOI: 10.1016/s1470-2045(19)30754-5


Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial. Lancet Oncol 2019; 20: 1432–43—In this Article, the National Institutes of Health and National Cancer Institute should have been included in the list of funders in the Summary. This correction has been made to the online version as of Jan 2, 2020.

中文翻译:

更名为《柳叶刀·昂科尔》(Lancet Oncol 2019); 20:1432-43。

Corn PG,Heath EI,Zurita A等。卡巴他赛加卡铂用于治疗转移性去势抵抗性前列腺癌的男性:一项随机,开放标签的1-2期临床试验。Lancet Oncol 2019; 20:1432-43 —在本文中,美国国立卫生研究院和美国国家癌症研究所应该列入摘要中的资助者名单。自2020年1月2日起对在线版本进行了更正。
更新日期:2020-01-04
down
wechat
bug